Reference : Indacaterol (Onbrez Breezhaler) et broncho-pneumopathie chronique obstructive.
Scientific journals : Article
Human health sciences : Cardiovascular & respiratory systems
Indacaterol (Onbrez Breezhaler) et broncho-pneumopathie chronique obstructive.
[en] Indacaterol (Onbrez Breezhaler) and chronic obstructive pulmonary disease
Corhay, Jean-Louis mailto [Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques]
Louis, Renaud mailto [Université de Liège - ULiège > Département des sciences cliniques > Pneumologie - Allergologie]
Revue Médicale de Liège
Université de Liège. Revue Médicale de Liège
Yes (verified by ORBi)
[en] indacaterol ; copd ; bronchodilator
[en] Indacaterol is a novel ultra long-acting beta 2-agonist (ultra-LABA), given once-daily, developed for the treatment of Chronic Obstructive Pulmonary Disease (COPD). The clinical studies suggest that indacaterol produces a rapid (within 5 minutes) and sustained bronchodilation (at least 24 hours) in patients with COPD. It improves also several important parameters as lung function, the quality of life, symptoms, exercise capacity, resting and dynamic hyperinflation, and exacerbations, while being well tolerated. These outcomes justify its use in moderate to very severe COPD patients. This review will give a brief summary of recent clinical data on the indacaterol, its comparison with other pharmacological agents used in the treatment of COPD, and also some information about its use in routine.

File(s) associated to this reference

Fulltext file(s):

Open access
indacatarol.pdfPublisher postprint398.4 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.